{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-112405","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.878477+00:00","generated_at":"2026-05-30T08:02:25.908356+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fennec Pharma appoints new CMO, CCO, CSO to accelerate growth","bullets":["Pierre Sayad appointed CMO, Terry Evans CCO, Christiana Cioffi CSO, effective Oct. 28, 2024.","Sayad receives $450,000 base salary and 150,000 options; Evans $400,000 + 150,000 options.","Cioffi receives $375,000 base salary and 150,000 options; each eligible for 40% target bonus.","All three executives have extensive oncology and rare disease launch experience.","Appointments aim to boost commercialization of PEDMARK for cisplatin-induced ototoxicity."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-112405","json":"https://secwatch.observer/filing/0001104659-24-112405.json","markdown":"https://secwatch.observer/filing/0001104659-24-112405.md","text":"https://secwatch.observer/filing/0001104659-24-112405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/0001104659-24-112405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/tm2427086d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:02:25.908356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b2d559657","claim":"Christiana Cioffi was appointed as Chief Strategy Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"Ms. Christiana Cioffi, MBA, as Chief Strategy Officer (\"CSO\"),","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/0001104659-24-112405-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Strategy Officer"}],"fact_type":"executive_change"},{"claim_id":"38efaa76bf","claim":"Pierre S. Sayad was appointed as Chief Medical Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"On October 28, 2024, Fennec Pharmaceuticals Inc.'s (the \"Company\") announced the appointments of Mr. Pierre S. Sayad, PhD, M.S., as Chief Medical Officer (\"CMO\"),","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/0001104659-24-112405-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"be1b5e267c","claim":"Terry Evans was appointed as Chief Commercial Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"Mr. Terry Evans as Chief Commercial Officer (\"CCO\"),","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/0001104659-24-112405-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}